Lorraine L. Rosamilia, MD
Dr. Rosamilia is from the Department of Dermatology, Geisinger Health System, State College, Pennsylvania.
Dr. Rosamilia reports no conflicts of interest in relation to this post.
The Journal of Investigative Dermatology recently published a Canadian population-based cohort study outlining the risk for inflammatory bowel disease (IBD) with isotretinoin use. It examined approximately 47,000 acne patients treated with isotretinoin, 185,000 patients treated with topical acne medications, and more than 1,500,000 untreated patients aged 12 to 29 years during a 12-year period. The authors concluded there was no primary association between isotretinoin and IBD but that subsets of patients on isotretinoin or topical acne therapy could be at risk; therefore, acne itself was postulated as the link. [More]